Hims & Hers sells telehealth subscriptions for hair loss, sexual health, skin care, mental health and weight loss. It grew very fast, partly on compounded weight-loss drugs, and regulatory changes around those drugs make the stock volatile.
| Company | Hims & Hers Health, Inc. |
| Ticker | HIMS |
| Listing | NYSE |
| Sector | Health Care |
| ISIN | US4330001060 |
| Headquarters | San Francisco, California, USA |
Hims & Hers at a glance
- Telehealth platform for hair, skin, sexual health and weight loss.
- Subscription revenue.
- Weight-loss medicines brought growth and regulatory attention.
A short history
Hims was founded in San Francisco in 2017, launched Hers for women in 2018 and listed through a SPAC in 2021. It has since added mental health, weight loss and other categories.
How Hims & Hers makes money
Customers pay monthly subscriptions that include online consultations with licensed providers and medication shipped from the company's pharmacies. Weight loss became a major growth category.
Competitive position
Hims has a strong consumer brand and personalised treatments. Competitors include Ro, other telehealth providers and pharmaceutical companies that now sell directly to patients. A large part of the weight-loss business has relied on compounded medicines, which depend on how regulators treat them.
What moves Hims & Hers stock
- Subscriber growth. The main volume driver.
- Weight loss products. Compounded GLP-1 drugs and branded partnerships.
- Personalised treatments. Higher-priced personalised plans.
- Marketing efficiency. Customer acquisition cost.
Hims & Hers key figures, up to date
HIMSThe AI stock analysis computes these figures from current market data, with a short comment on each number and the method behind the fair value range.
Free for 7 days. Not investment advice.
The numbers worth checking
Not every ratio matters equally for every company. For Hims & Hers, these are the figures that tell you the most. If a term is new, the guides on the P/E ratio and fair value explain the basics.
- Subscribers. Reported quarterly.
- Revenue per subscriber. Monthly online revenue per average subscriber.
- Adjusted EBITDA margin. Profitability trend.
- Marketing as a share of revenue. Shows efficiency.
The best source for these figures is the latest annual or quarterly report on the Hims & Hers investor relations site. Our guide on how to read an earnings report shows where to find them.
How to think about valuation
Hims is valued on EV/EBITDA and growth. Investors watch subscriber growth and revenue per subscriber.
Opportunities
- Weight loss. Large market.
- New categories. Testosterone, menopause and more.
- International. Expansion to Europe.
Risks to keep in view
- Regulation of compounded drugs. The FDA ended shortage-based compounding of semaglutide.
- Partner disputes. Partnerships with drug makers can end.
- Short interest and volatility. The stock moves sharply on news.
A useful exercise is to write the bull case and the bear case for Hims & Hers in three sentences each. If you cannot fill the bear case, you have not looked hard enough. How to write an investment thesis walks through it.
What to watch in the next report
- Subscriber growth
- Weight-loss revenue
- Regulation of compounded medicines
How to research Hims & Hers stock with Peakwise
The quickest way to put the points above against current figures is the AI stock analysis: search for Hims & Hers, generate the report and check the executive summary, the financials and the fair value range. The report states the method behind its estimate, so you can see which assumptions drive it.
For anything the report leaves open, ask the investment chatbot. It runs a web search for each question and links the sources it used, so you can open them and check. A good first question:
How did Hims & Hers change its weight loss offering after the FDA ended the semaglutide shortage?
To look at the chart itself, the AI chart analysis describes trend, support and resistance levels and patterns over one month, one year and the full history.
Related research
- Novo Nordisk stock analysis
- Eli Lilly stock analysis
- UnitedHealth stock analysis
- How to compare two stocks
- How to research a stock in 10 minutes
This article describes the business and the questions worth asking. It contains no price targets and no forecasts, and it is not investment advice. Check current figures before you make a decision.